FDA Approves Vemurafenib for Erdheim-Chester Disease
Nov 05
2017
The Food and Drug Administration granted regular approval to vemurafenib (ZELBORAF, Hoffmann-La Roche Inc.) for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.